Register for our free email digests:
Illumina Inc.
www.illumina.com
Latest From Illumina Inc.
The Only Way Is Nasdaq – Part One
The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.
Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
J.P. Morgan Stockwatch: No Substitute For M&A
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Services
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Illumina Inc.
- Senior Management
-
Francis deSouza, Pres. & CEO
Sam Samad, CFO
Mark Van Oene, SVP, Chief Commercial Officer
Garrett Hampton, PhD, EVP, Clinical Genomics
Omead Ostadan, EVP, Products & Ops
Joydeep Goswami, SVP, Corp Dev. & Strategic Planning
Mostafa Ronaghi, PhD, SVP, CTO - Contact Info
-
Illumina Inc.
Phone: (858) 202-4500
5200 Illumina Way
San Diego, CA 92122
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice